Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01769196 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 544
- Enrollment target
NCT01769196 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 544 participants.
The verdict
NCT01769196, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 544 participants
- Enrollment target
Study Summary
The primary objectives of this study are to determine the effect of simtuzumab (GS-6624) on progression-free survival (PFS) as determined by either a categorical decline in forced vital capacity (FVC) or all-cause mortality, in all participants enrolled or in a subset of participants who are classified as lysyl oxidase-like-2 (LOXL2) high based on a prespecified level in serum at baseline.
Interventions
- DRUG Simtuzumab
- DRUG Simtuzumab placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 544 participants |
| Start Date | 2013-01-31 |
| Est. Completion | 2016-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01769196
The ClinicalTrials.gov registry entry for NCT01769196 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 544 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Simtuzumab is the first listed.
NCT01769196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01769196 about?
NCT01769196 is a clinical study titled "Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)". The primary objectives of this study are to determine the effect of simtuzumab (GS-6624) on progression-free survival (PFS) as determined by either a categorical decline in forced vital capacity (FVC) or all-cause mortality, in all participants enrolled or in a subset of participants who are classif...
What is the current status of trial NCT01769196?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 544 participants. The study started on 2013-01-31. Estimated completion is 2016-02-23.
What interventions are being tested in trial NCT01769196?
The interventions under investigation include: Simtuzumab (DRUG), Simtuzumab placebo (DRUG).
Who is sponsoring clinical trial NCT01769196?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.